A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.
Canada
Patient-reported outcomes
health policy
implementation science
patient experiences
patient-reported outcome measures
proms
pros
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
11
8
2020
Statut:
ppublish
Résumé
Patient-reported outcomes (pros) are essential to capture the patient's perspective and to influence care. Although pros and pro measures are known to have many important benefits, they are not consistently being used and there is there no Canadian pros oversight. The Position Statement presented here is the first step toward supporting the implementation of pros in the Canadian health care setting. The Canadian pros National Steering Committee drafted position statements, which were submitted for stakeholder feedback before, during, and after the first National Canadian Patient Reported Outcomes (canpros) scientific conference, 14-15 November 2019 in Calgary, Alberta. In addition to the stakeholder feedback cycle, a patient advocate group submitted a section to capture the patient voice. The canpros Position Statement is an outcome of the 2019 canpros scientific conference, with an oncology focus. The Position Statement is categorized into 6 sections covering 4 theme areas: Patient and Families, Health Policy, Clinical Implementation, and Research. The patient voice perfectly mirrors the recommendations that the experts reached by consensus and provides an overriding impetus for the use of pros in health care. Although our vision of pros transforming the health care system to be more patient-centred is still aspirational, the Position Statement presented here takes a first step toward providing recommendations in key areas to align Canadian efforts. The Position Statement is directed toward a health policy audience; future iterations will target other audiences, including researchers, clinicians, and patients. Our intent is that future versions will broaden the focus to include chronic diseases beyond cancer.
Sections du résumé
Background
Patient-reported outcomes (pros) are essential to capture the patient's perspective and to influence care. Although pros and pro measures are known to have many important benefits, they are not consistently being used and there is there no Canadian pros oversight. The Position Statement presented here is the first step toward supporting the implementation of pros in the Canadian health care setting.
Methods
The Canadian pros National Steering Committee drafted position statements, which were submitted for stakeholder feedback before, during, and after the first National Canadian Patient Reported Outcomes (canpros) scientific conference, 14-15 November 2019 in Calgary, Alberta. In addition to the stakeholder feedback cycle, a patient advocate group submitted a section to capture the patient voice.
Results
The canpros Position Statement is an outcome of the 2019 canpros scientific conference, with an oncology focus. The Position Statement is categorized into 6 sections covering 4 theme areas: Patient and Families, Health Policy, Clinical Implementation, and Research. The patient voice perfectly mirrors the recommendations that the experts reached by consensus and provides an overriding impetus for the use of pros in health care.
Conclusions
Although our vision of pros transforming the health care system to be more patient-centred is still aspirational, the Position Statement presented here takes a first step toward providing recommendations in key areas to align Canadian efforts. The Position Statement is directed toward a health policy audience; future iterations will target other audiences, including researchers, clinicians, and patients. Our intent is that future versions will broaden the focus to include chronic diseases beyond cancer.
Identifiants
pubmed: 32489251
doi: 10.3747/co.27.6399
pii: conc-27-90
pmc: PMC7253746
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-99Informations de copyright
2020 Multimed Inc.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and with the exceptions of the authors listed below, we declare that we have none or were unable to respond to the request for disclosures because of covid-19–related activities. LB has received an honorarium from Genentech and travel support from Elekta. AFK has received consulting fees from Allergan. RO has received grant funding from Varian Medical Systems.
Références
Qual Life Res. 2010 Apr;19(3):371-9
pubmed: 20146009
Med Care. 2015 Feb;53(2):153-9
pubmed: 25588135
Health Serv Insights. 2013 Aug 04;6:61-8
pubmed: 25114561
Support Care Cancer. 2018 Jan;26(1):41-60
pubmed: 28849277
J Clin Oncol. 2004 Feb 15;22(4):714-24
pubmed: 14966096
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Health Aff (Millwood). 2008 May-Jun;27(3):759-69
pubmed: 18474969
BMC Health Serv Res. 2013 Jun 11;13:211
pubmed: 23758898
J Eval Clin Pract. 2020 Apr;26(2):524-540
pubmed: 31840346
CA Cancer J Clin. 2012 Sep-Oct;62(5):337-47
pubmed: 22811342
J Oncol Pract. 2012 Nov;8(6):e142-8
pubmed: 23598849
Health Qual Life Outcomes. 2019 Oct 16;17(1):156
pubmed: 31619266
J Comp Eff Res. 2016 Aug;5(5):507-19
pubmed: 27427277
Br J Dermatol. 2007 May;156(5):929-37
pubmed: 17381458
J Clin Oncol. 2001 Nov 1;19(21):4117-25
pubmed: 11689579
Value Health. 2015 Jun;18(4):493-504
pubmed: 26091604
Ann Oncol. 2015 Sep;26(9):1846-1858
pubmed: 25888610
Am Soc Clin Oncol Educ Book. 2017;37:695-704
pubmed: 28561689
J Clin Oncol. 2011 Mar 10;29(8):1029-35
pubmed: 21282548
JAMA. 2002 Dec 18;288(23):3027-34
pubmed: 12479768
N Engl J Med. 2017 Jan 12;376(2):105-108
pubmed: 28076708
Nat Rev Clin Oncol. 2017 Dec;14(12):763-772
pubmed: 28975931
Am Soc Clin Oncol Educ Book. 2018 May 23;38:122-134
pubmed: 30231381
Qual Life Res. 2019 Feb;28(2):345-356
pubmed: 30306533
Nat Rev Clin Oncol. 2017 Sep;14(9):529-530
pubmed: 28719587
Support Care Cancer. 2019 Jul;27(7):2579-2589
pubmed: 30446857
Qual Life Res. 2015 Jul;24(7):1707-18
pubmed: 25589231
J Patient Rep Outcomes. 2018 Dec 27;2(1):64
pubmed: 30588562
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Ann Oncol. 2017 Oct 1;28(10):2332-2333
pubmed: 28961852
Healthc Pap. 2011;11(4):42-7; discussion 55-8
pubmed: 22543292
J Clin Oncol. 2011 Mar 10;29(8):994-1000
pubmed: 21282546
J Eval Clin Pract. 2006 Oct;12(5):559-68
pubmed: 16987118
Mayo Clin Proc. 2019 Nov;94(11):2291-2301
pubmed: 31563425
J Clin Oncol. 2014 May 10;32(14):1480-501
pubmed: 24711559
Patient Relat Outcome Meas. 2018 Nov 01;9:353-367
pubmed: 30464666
Palliat Support Care. 2014 Feb;12(1):39-51
pubmed: 23942274
Patient Educ Couns. 2006 Oct;63(1-2):12-23
pubmed: 16406464
Support Care Cancer. 2020 Feb 4;:
pubmed: 32020357
Healthc Manage Forum. 2018 Jan;31(1):13-17
pubmed: 29264976
Cancer. 2016 Feb 1;122(3):355-7
pubmed: 26619153